Kalaris Therapeutics Inc
NASDAQ:KLRSBiotechnology
+$0.16 today
- Market cap
- $54.75M
- Beta
- 0.14
- P/E (TTM)
- -2.5
- EPS (TTM)
- -$1.86
Volume 0.07M
Average 0.08M
KLRS Free Cash Flow
Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.
Kalaris Therapeutics IncNASDAQ: KLRS
Free Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Free cash flow grows 79.4% year over year
Q1 FY2026 free cash flow of $13.35M (cash outflow) rose 79.4% year over year. Sequentially, it rose 43.0% from the prior quarter. Over 3 fiscal years it compounded at +64.1% a year.
Context
- Free cash flow grew in size in 2 of the last 3 fiscal years.
Sources:Cash FlowText generated from reported figures; not investment advice.
Free Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (43.18M) USD
- Year-over-year change
- +36.2%
| Period | Period end | Free Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (43.18M) | +36.2% |
| FY2024 | 2024-12-31 | (67.71M) | -379.1% |
| FY2023 | 2023-12-31 | (14.13M) | -44.5% |
| FY2022 | 2022-12-31 | (9.78M) | +90.8% |
| FY2021 | 2021-12-31 | (106.35M) | — |
Free Cash Flow vs competitors
How KLRS compares with its peers on the latest reported figures
- Peers report in different currencies, so free cash flow is compared through growth and share of revenue rather than absolute size.
- Over three fiscal years its annual growth of +64.1% compares with a peer median of -6.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $152.14M USD | -23.4% | +246.3% | 152.7% | |
ARTVArtiva Biotherapeutics, Inc. | LTM Mar 2026 | $80.18M USD | +31.6% | +11.6% | — |
IMAImageneBio Inc | LTM Mar 2026 | $52.08M USD | +36.1% | -14.1% | — |
| FY2025 | $51.64M USD | +112.0% | -20.7% | 80687.5% | |
KLRSKalaris Therapeutics Inc | LTM Mar 2026 | $49.09M USD | — | +64.1% | — |
| LTM Mar 2026 | $41.95M USD | -15.4% | -12.2% | 589.1% | |
| LTM Mar 2026 | $41.28M USD | -26.9% | -27.8% | 4128.2% | |
| LTM Mar 2026 | $32.82M USD | +115.0% | +23.3% | — | |
| LTM Mar 2026 | €28.93M EUR | -39.4% | +0.1% | 98624.1% | |
| Peer median (excluding KLRS) | — | +8.1% | -6.0% | 4128.2% | |
Competitors are the stored peer set for KLRS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (171.96M) | (15.49M) | (14.7M) | (58.77M) | (43.44M) |
| Depreciation & Amortization | 1.12M | 0 | 0 | 0 | 13K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 271K | 148K | 0 | 0 |
| Change in Working Capital | 19.35M | 3.4M | (1.09M) | (25.31M) | 3.43M |
| Accounts Receivables | 400K | 0 | 0 | 206K | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 20.29M | 1.83M | (402K) | (28.86M) | (88K) |
| Other Working Capital | (1.34M) | 1.57M | (690K) | 3.35M | 3.52M |
| Other Non-Cash Items | 45.17M | 2.04M | 1.51M | 16.37M | (2.98M) |
| Operating Cash Flow | (106.32M) | (9.78M) | (14.13M) | (67.71M) | (42.98M) |
| Capital Expenditures | (26K) | 0 | 0 | 0 | (200K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (76.59M) | 0 | 0 | 0 | (34.52M) |
| Sales of Investments | 262.6M | 0 | 0 | 95M | 15M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 185.98M | 0 | 0 | 95M | (19.72M) |
| Debt Repayment | 0 | 4.3M | 6M | 0 | 7.5M |
| Common Stock Issued | 232K | 0 | 0 | 21K | 50M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 5K | 1.5M | 0 | 102.11M |
| Financing Cash Flow | 232K | 12.78M | 14.24M | 21K | 159.61M |
| Effect of Forex Changes | (896K) | 0 | 0 | 852K | (117.15M) |
| Net Change in Cash | 79M | 3M | 110K | 28.17M | (20.24M) |
| Free Cash Flow | (106.35M) | (9.78M) | (14.13M) | (67.71M) | (43.18M) |
Kalaris Therapeutics Inc
NASDAQ:KLRS
Intrinsic Alpha fair value
Locked
Current Price
$2.30
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.